Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model
This cost-effectiveness analysis demonstrates that ofatumumab is a cost-effective treatment for RRMS in Saudi Arabia, with an ICER below the WTP. Policymakers should consider including ofatumumab in national formularies and prioritize its use in early-stage RRMS to maximize patient benefit and cost-effectiveness.
Authors
- Saja Almazrou (ORCID: https://orcid.org/0000-0002-9307-2913)
- Abdulrahman A. Alsuhibani (ORCID: https://orcid.org/0000-0003-4852-1166)
- Fahad Obaid Alotaibi
- Ziyad S. Almalki (ORCID: https://orcid.org/0000-0003-1618-4142)
- Abdullah K. Alahmari (ORCID: https://orcid.org/0000-0002-1047-6913)
- Mai Khalid Alshammari
- Bushra Yousif Asiri
- Tala Nouraldin Alalawi
- Ohud Abd Alhadi Alqahtani
- Maryam Riyadh Alkhayat
- Shahad Fahad Alnemari
- Haya Showky Mukhemair
- Sara Mohamaad Alkredeas
Institutions
- Alfaisal University (SA)
- Prince Sattam Bin Abdulaziz University (SA)
- Qassim University (SA)
- King Saud University (SA)
- Ministry of Health (SA)
- Almaarefa University
Publication Details
- Journal
- ClinicoEconomics and Outcomes Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/ceor.s503842
- Citations
- 4
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.89
Funders
- Prince Sattam bin Abdulaziz University